Anti-Inflamatory Drug for Myocardial Injury in Acute Coronary Syndrome

Area of Science:

• Cardiology
• Pharmacology
• Inflammation Research

Background:

• Acute coronary syndrome (ACS), including ST-elevation myocardial infarction (STEMI), has high mortality rates despite advanced treatments like primary percutaneous coronary intervention (PCI).
• STEMI prevalence is rising globally and in Indonesia, highlighting the need for improved therapeutic strategies.
• Colchicine, an anti-inflammatory agent derived from the Colchicum autumnale plant, has demonstrated potential in managing cardiovascular inflammation.

Purpose of the Study:

• To explore the potential of colchicine in reducing mortality rates among STEMI patients.
• To investigate the anti-inflammatory mechanisms of colchicine relevant to atherothrombosis in ACS.
• To assess the current evidence and identify gaps in clinical studies regarding colchicine's efficacy in ACS, particularly STEMI.

Main Methods:

• Review of existing epidemiological data on ACS and STEMI prevalence.
• Analysis of colchicine's known anti-inflammatory actions, including effects on neutrophil expression and platelet interaction.
• Synthesis of findings from previous studies investigating colchicine in various coronary artery disease settings.

Main Results:

• Colchicine exhibits anti-inflammatory properties by decreasing neutrophil L-selectin expression and interfering with neutrophil-platelet interactions, potentially mitigating atherothrombosis.
• While colchicine is known to reduce inflammatory markers in ACS and is generally considered safe, its clinical effectiveness in reducing STEMI mortality remains unclear.
• Existing research on colchicine's benefit in ACS, especially STEMI, is limited and yields varied results.

Conclusions:

• The anti-inflammatory mechanism of colchicine suggests a potential role in managing STEMI.
• Further comprehensive research and robust clinical trials are essential to establish the definitive role and efficacy of colchicine in treating acute coronary syndromes.
• Ongoing studies are crucial for providing supporting clinical evidence for colchicine's use in ACS management.